A Phase 1 interventional study of [14C]HLX208 in Mass Balance Study in Healthy Subjects, sponsored by Shanghai Henlius Biotech. Completed at 1 site in China. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-01-16.
Sponsored by Shanghai Henlius Biotech (part of Fosun Pharma) · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Mass Balance Study of [14C]HLX208 in China Healthy Subjects.
A phase I study to quantify the total mass balance in healthy subjects after a single dose of [14C]HLX208.
Shanghai Henlius Biotech is the lead sponsor of 132 studies on the registry; 56 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single oral dose of 450mg \[14C\]HLX208 suspension.
Drug: [14C]HLX208
Carbon-14 labeled HLX208
Mass balance recovery of total radioactivity in urine and fecal samples.
Mass balance recovery of total radioactivity in urine and fecal samples.
Time frame: Up to 336 hours post dose.
Total radioactivity in plasma PK: Cmax
Maximum plasma concentration
Time frame: Up to 240 hours post dose.
Total radioactivity in plasma PK: Tmax
Time for Cmax
Time frame: Up to 240 hours post dose.
Total radioactivity in plasma PK: AUC0-t
Area under the plasma concentration time profile from time 0 to time of the last quantifiable concentration.
Time frame: Up to 240 hours post dose.
Total radioactivity in plasma PK: AUC0-∞
Area under the plasma concentration time profile from time 0 to infinity.
Time frame: Up to 240 hours post dose.
Total rradioactivity in plasma PK: t1/2
Elimination half-life.
Time frame: Up to 240 hours post dose.
Total radioactivity in plasma PK: CL/F
Drug clearance.
Time frame: Up to 240 hours post dose.
Total radioactivity in plasma PK: Vz/F
Apparent volume of distribution following oral administration.
Time frame: Up to 240 hours post dose.
HLX208 and metabolite PK: Cmax
Maximum plasma concentration
Time frame: Up to 240 hours post dose.
HLX208 and metabolite PK: Tmax
Time for Cmax
Time frame: Up to 240 hours post dose.
HLX208 and metabolite PK: AUC0-t
Area under the plasma concentration time profile from time 0 to time of the last quantifiable concentration.
Time frame: Up to 240 hours post dose.
HLX208 and metabolite PK: AUC0-∞
Area under the plasma concentration time profile from time 0 to infinity.
Time frame: Up to 240 hours post dose.
HLX208 and metabolite PK: t1/2
Elimination half-life.
Time frame: Up to 240 hours post dose.
Adverse events
Number of adverse events, which are any untoward medical occurrence regardless of attribution to study drug in a participant who received study drug.
Time frame: Screening up to Day 15
Plan to share: No
No publications or documents are linked to this record.
Ran from Jun 2023 to primary completion in Jul 2023, 0 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: BRAF V600E Inhibitor HLX208